LGND
Ligand Pharmaceuticals Incorporated
NasdaqGMUSDEQUITY
DELAYED
Last price
286.29
▼ 1.10 (0.38%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
287.99
Prev close
287.39
Day high
289.98
Day low
285.21
Volume
141.86K
Market cap
—
P/E (TTM)
—
52W range
157.52 – 326.63
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-2.82%
-1.5%
1M
-5.25%
-9.0%
3M
+28.85%
+25.8%
6M
+55.61%
+44.5%
YTD
+51.42%
+39.1%
1Y
+84.41%
+64.4%
3Y
+328.39%
+254.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $268.09M | $167.13M | $131.31M | $196.25M | +60.4% |
| Operating revenue | $268.09M | $167.13M | $131.31M | $196.25M | +60.4% |
| Cost of revenue | $14.55M | $11.07M | $10.51M | $52.83M | +31.4% |
| Gross profit | $253.54M | $156.06M | $120.80M | $143.42M | +62.5% |
| Research & development | $81.18M | $21.43M | $24.54M | $36.08M | +278.9% |
| Selling, general & admin | $92.45M | $78.65M | $52.79M | $70.06M | +17.5% |
| Total operating expense | $206.34M | $133.04M | $110.98M | $140.38M | +55.1% |
| Operating income | $47.20M | $23.02M | $9.82M | $3.04M | +105.0% |
| Net interest income | $8.94M | $5.02M | $7.05M | $247.00K | +78.2% |
| Pre-tax income | $158.96M | $2.52M | $63.66M | $36.01M | +6,212.9% |
| Tax provision | $34.51M | $6.55M | $9.84M | $41.23M | +426.8% |
| Net income | $124.45M | -$4.03M | $52.15M | -$33.36M | +3,186.6% |
| Net income to common | $124.45M | -$4.03M | $52.15M | -$33.36M | +3,186.6% |
| Basic EPS | 6.44 | -0.22 | 3.02 | -1.98 | +3,027.3% |
| Diluted EPS | 6.13 | -0.22 | 2.94 | -1.98 | +2,886.4% |
| EBIT | $163.68M | $5.55M | $64.32M | $37.81M | +2,846.4% |
| EBITDA | $197.45M | $40.79M | $100.84M | $89.34M | +384.0% |
| Basic shares | 19.34M | 18.29M | 17.30M | 16.87M | +5.7% |
| Diluted shares | 20.29M | 18.29M | 17.76M | 16.87M | +11.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $174.93M | $72.31M | $22.95M | $45.01M | — | +141.9% |
| Cash & short-term investments | $756.31M | $266.19M | $170.31M | $211.87M | — | +184.1% |
| Accounts receivable | $59.60M | $38.38M | $32.92M | $30.42M | — | +55.3% |
| Inventory | $9.13M | $14.11M | $23.97M | $13.29M | — | -35.3% |
| Total current assets | $832.27M | $331.56M | $237.43M | $263.60M | — | +151.0% |
| Property, plant & equipment | $10.79M | $24.81M | $25.06M | $27.49M | — | -56.5% |
| Goodwill & intangibles | $326.98M | $371.90M | $402.98M | $458.31M | — | -12.1% |
| Total assets | $1.56B | $941.77M | $787.22M | $762.67M | — | +65.7% |
| Total current liabilities | $37.45M | $37.11M | $16.78M | $98.81M | — | +0.9% |
| Current debt | — | — | — | $76.69M | — | — |
| Long-term debt | $446.19M | — | — | — | $320.72M | — |
| Total debt | $451.49M | $7.08M | $6.17M | $87.75M | — | +6,276.1% |
| Total liabilities | $543.42M | $111.33M | $86.30M | $165.18M | — | +388.1% |
| Retained earnings | $608.09M | $498.98M | $503.02M | $450.86M | — | +21.9% |
| Shareholder equity | $1.02B | $830.44M | $700.91M | $597.49M | — | +22.5% |
| Working capital | $794.82M | $294.45M | $220.65M | $164.79M | — | +169.9% |
| Net tangible assets | $690.23M | $458.54M | $297.94M | $139.18M | — | +50.5% |
| Shares issued | 19.77M | 19.11M | 17.56M | 16.95M | — | +3.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $124.45M | -$4.03M | $52.15M | -$33.36M | +3,186.6% |
| Depreciation & amortisation | $33.77M | $35.24M | $36.52M | $51.53M | -4.2% |
| Stock-based compensation | $46.85M | $41.09M | $25.74M | $60.28M | +14.0% |
| Change in working capital | -$12.66M | $19.36M | -$34.40M | $65.68M | -165.4% |
| Operating cash flow | $49.36M | $97.05M | $49.58M | $137.85M | -49.1% |
| Capital expenditure | -$11.31M | -$19.64M | -$53.85M | -$17.92M | +42.4% |
| Investing cash flow | -$377.32M | -$143.66M | -$11.68M | $163.62M | -162.6% |
| Share buybacks | -$15.00M | $0 | $0 | $0 | — |
| Financing cash flow | $428.22M | $97.14M | -$59.95M | -$275.99M | +340.8% |
| Free cash flow | $38.05M | $77.41M | -$4.27M | $119.93M | -50.9% |
| End cash position | $174.93M | $72.31M | $22.95M | $45.01M | +141.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $63.69M | $51.72M | $59.67M | $115.46M | $47.63M | +23.1% |
| Operating revenue | $63.69M | $51.72M | $59.67M | $115.46M | $47.63M | +23.1% |
| Cost of revenue | $3.21M | $3.27M | $2.99M | $3.80M | $2.91M | -1.8% |
| Gross profit | $60.48M | $48.45M | $56.67M | $111.66M | $44.72M | +24.8% |
| Research & development | $14.67M | $2.15M | $3.51M | $21.02M | $6.57M | +582.9% |
| Selling, general & admin | $29.12M | $20.84M | $25.03M | $28.45M | $20.18M | +39.8% |
| Total operating expense | $51.89M | $31.08M | $36.63M | $57.56M | $35.00M | +66.9% |
| Operating income | $8.59M | $17.37M | $20.04M | $54.10M | $9.72M | -50.5% |
| Net interest income | $5.55M | $4.91M | $4.61M | $2.96M | $468.00K | +13.1% |
| Pre-tax income | $64.30M | -$24.26M | $56.78M | $141.14M | $11.22M | +365.1% |
| Tax provision | $15.80M | -$10.91M | $12.00M | $23.86M | $6.38M | +244.7% |
| Net income | $48.51M | -$13.35M | $44.78M | $117.27M | $4.85M | +463.5% |
| Net income to common | $48.51M | -$13.35M | $44.78M | $117.27M | $4.85M | +463.5% |
| Basic EPS | 2.42 | -0.67 | 2.27 | 5.99 | 0.25 | +461.2% |
| Diluted EPS | 2.22 | -0.67 | 2.12 | 5.68 | 0.24 | +431.3% |
| EBIT | $66.05M | -$22.51M | $58.56M | $142.05M | $12.38M | +393.4% |
| EBITDA | $74.27M | -$14.30M | $66.78M | $150.32M | $20.90M | +619.5% |
| Basic shares | 20.06M | 19.88M | 19.73M | 19.58M | 19.33M | +0.9% |
| Diluted shares | 21.84M | 19.88M | 21.14M | 20.63M | 19.93M | +9.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.01B | $115.08M | $174.93M | $139.38M | $67.67M | +774.8% |
| Cash & short-term investments | $1.37B | $791.56M | $756.31M | $676.94M | $255.30M | +73.2% |
| Accounts receivable | $67.01M | $53.38M | $59.60M | $57.56M | $41.29M | +25.5% |
| Inventory | $8.66M | $11.47M | $9.13M | $9.60M | $12.89M | -24.4% |
| Total current assets | $1.46B | $865.41M | $832.27M | $753.92M | $352.94M | +68.4% |
| Property, plant & equipment | $9.84M | $10.28M | $10.79M | $11.07M | $11.62M | -4.3% |
| Goodwill & intangibles | $310.79M | $318.88M | $326.98M | $335.08M | $351.67M | -2.5% |
| Total assets | $2.19B | $1.53B | $1.56B | $1.48B | $948.60M | +42.7% |
| Total current liabilities | $46.74M | $40.67M | $37.45M | $30.54M | $64.73M | +14.9% |
| Long-term debt | $1.13B | $446.90M | $446.19M | $445.49M | — | +152.1% |
| Total debt | $1.13B | $451.98M | $451.49M | $451.00M | $5.74M | +150.3% |
| Total liabilities | $1.22B | $534.78M | $543.42M | $526.60M | $120.08M | +127.8% |
| Retained earnings | $583.25M | $594.74M | $608.09M | $578.22M | $461.38M | -1.9% |
| Shareholder equity | $967.52M | $997.32M | $1.02B | $950.17M | $828.53M | -3.0% |
| Working capital | $1.41B | $824.75M | $794.82M | $723.38M | $288.21M | +71.0% |
| Net tangible assets | $656.73M | $678.44M | $690.23M | $615.10M | $476.86M | -3.2% |
| Shares issued | 19.92M | 20.03M | 19.77M | 19.66M | 19.41M | -0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $48.51M | -$13.35M | $44.78M | $117.27M | $4.85M | +463.5% |
| Depreciation & amortisation | $8.21M | $8.22M | $8.21M | $8.27M | $8.52M | -0.0% |
| Stock-based compensation | $13.65M | $10.60M | $14.27M | $14.75M | $10.00M | +28.9% |
| Change in working capital | -$7.00M | $5.88M | $9.29M | -$10.62M | -$6.17M | -219.0% |
| Operating cash flow | $24.02M | $48.69M | $45.91M | $13.09M | $15.80M | -50.7% |
| Capital expenditure | -$2.67M | -$228.00K | -$659.00K | -$8.41M | -$214.00K | -1,069.3% |
| Investing cash flow | $321.12M | -$94.35M | -$18.10M | -$353.44M | -$10.67M | +440.4% |
| Share buybacks | — | — | $0 | -$15.00M | — | — |
| Financing cash flow | $546.43M | -$14.13M | $8.33M | $409.64M | $14.99M | +3,966.4% |
| Free cash flow | $21.35M | $48.46M | $45.26M | $4.68M | $15.59M | -55.9% |
| End cash position | $1.01B | $115.09M | $174.93M | $139.38M | $67.67M | +774.7% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
290.49
-1.45% from price
SMA 20
292.96
-2.28% from price
SMA 50
294.20
-2.69% from price
SMA 100
259.06
+10.51% from price
SMA 200
228.25
+25.43% from price
EMA 12
291.00
-1.62% from price
EMA 26
292.42
-2.10% from price
EMA 50
285.31
+0.34% from price
RSI (14)
44.8
Neutral
MACD (12,26,9)
-1.42
Hist -1.38
ATR (14)
10.28
3.59% of price
Realised vol 30D
30.0%
Annualised
Bollinger upper
302.54
20, 2σ
Bollinger lower
283.38
20, 2σ
50 / 200 cross
Golden
294.20 vs 228.25
Trend bias
Above 200
+25.43%
Risk profile
Beta vs SPY
0.80
Less volatile than market
Correlation to SPY
0.29
Largely independent
Realised vol 30D
30.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-14.1%
Peak to trough
Max drawdown 5Y
-55.1%
Peak to trough
ATR 14
10.28
3.59% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Breakout Watch: Savvy Investors Bet Millions On Royalty-Fueled Pharma Stock
Investor's Business Daily · 8d ago
Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run
Simply Wall St. · 9d ago
Ligand Pharmaceuticals (LGND) Reaffirms 2026 Guidance, Is The Stock Fully Priced?
Simply Wall St. · 9d ago
Ligand (LGND) Q2 2026 Earnings Call Transcript
Motley Fool · 9d ago
Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
GlobeNewswire · 12d ago
LGND: XOMA Acquisition Closed
Zacks Small Cap Research · 13d ago
RBC Adjusts PT on Ligand Pharmaceuticals to $345 From $340, Maintains Outperform Rating
MT Newswires · 15d ago
Ligand Pharmaceuticals Inc (LGND) (Q2 2026) Earnings Call Highlights: Royalty Revenue Surges ...
GuruFocus.com · 16d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.